research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-25 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
When a crystalline aqueous suspension of steroid is administered via intramuscular injection, a crystalline depot suspended in fluid is formed locally within the muscle. These crystals slowly dissolve and the steroid is gradually absorbed into the body, resulting in the long durations of such preparations. Particle sizes of 10 μm or less have no apparent depot effect. A larger needle size is needed for aqueous suspensions of steroids to allow the steroid crystals to pass through the needle lumen. Aqueous suspensions pose a risk of injection site reactions such as local irritation, swelling, and redness, with often severe pain. The reactions are worse with larger crystal sizes. Particle sizes of more than 300 μm in the case of estradiol benzoate have been found to be too painful for use. The local injection site reactions, which do not occur with oil solutions, have limited the clinical use of aqueous suspensions of estradiol and its esters as well as other steroids.
In bioinformatics and biochemistry, the FASTA format is a text-based format for representing either nucleotide sequences or amino acid (protein) sequences, in which nucleotides or amino acids are represented using single-letter codes. The format allows for sequence names and comments to precede the sequences. It originated from the FASTA software package and has since become a near-universal standard in bioinformatics. The simplicity of FASTA format makes it easy to manipulate and parse sequences using text-processing tools and scripting languages.
=== Color space, dynamic range, frame rate and resolution/aliasing === The human visual system has a limited ability to discern improvements in resolution when picture elements are already small enough or distant enough from the viewer. At some home viewing distances and up to 60-70" TV sizes, HD resolution is near the limits of resolution for the eye and increasing resolution to 4K has little perceptual impact, if consumers are beyond the critical distance (Lechner distance) to appreciate the differences in pixel count between 4K and HD. One exception is that even if resolution surpasses the resolving ability of the human eye, there is still an improvement in the way the image appears due to higher resolutions reducing spatial aliasing. UHDTV provides other image enhancements in addition to pixel density. Specifically, dynamic range and color are greatly enhanced, and these readily resolved saturation and contrast differences greatly improve the experience of 4KTV compared to HDTV. UHDTV allows the use of the Rec. 2020 (UHDTV) color space which can reproduce colors that cannot be shown with the Rec. 709 (HDTV) color space. In terms of CIE 1931 color space, the Rec. 2020 color space covers 75.8%, compared to coverage by the DCI-P3 digital cinema reference projector color space of just 53.6%, 52.1% by Adobe RGB color space, while the Rec. 709 color space covers only 35.9%. UHDTV's increases in dynamic range allow not only brighter highlights but also increased detail in the greyscale. UHDTV also allows for frame rates up to 120 frames per second (fps).
== Function == BMPs interact with specific receptors on the cell surface, referred to as bone morphogenetic protein receptors (BMPRs). Signal transduction through BMPRs results in mobilization of members of the SMAD family of proteins. The signaling pathways involving BMPs, BMPRs and SMADs are important in the development of the heart, central nervous system, and cartilage, as well as post-natal bone development. They have an important role during embryonic development on the embryonic patterning and early skeletal formation. As such, disruption of BMP signaling can affect the body plan of the developing embryo. For example, BMP4 and its inhibitors noggin and chordin help regulate polarity of the embryo (i.e. back to front patterning). Specifically BMP-4 and its inhibitors play a major role in neurulation and the development of the neural plate. BMP-4 signals ectoderm cells to develop into skin cells, but the secretion of inhibitors by the underlying mesoderm blocks the action of BMP-4 to allow the ectoderm to continue on its normal course of neural cell development. Additionally, secretion of BMPs by the roof plate in the developing spinal cord helps to specify dorsal sensory interneurons. As a member of the transforming growth factor-beta superfamily, BMP signaling regulates a variety of embryonic patterning during fetal and embryonic development. For example, BMP signaling controls the early formation of the Müllerian duct (MD) which is a tubular structure in early embryonic developmental stage and eventually becomes female reproductive tracts.
Sources: en.wikipedia.org
13 September Space - the Final Junkyard, about space debris; Nick Johnson of NASA; Paul Maley of United Space Alliance, and JSC Astronomical Society; Mark Mulrooney of the NASA Orbital Debris Observatory, and its liquid-mirror telescope; Scott J. Horowitz; Pam McCraw of Mission Operations Directorate at the Johnson Space Center in Texas; the Institute for Advanced Technology at the University of Texas at Austin; Richard Crowther of the Defence Evaluation and Research Agency; Don Kessler of NASA JSC; the French reconnaissance Cerise (satellite), which was damaged on 24 July 1996 by debris from Ariane; Darren McKnight and Kosmos 1275, launched on 4 June 1981, and was damaged on 24 July 1981; on 24 January 1978, the nuclear-powered Kosmos 954, a RORSAT, crashed into Canada; The Aerospace Corporation; the Russian Mars 96 was launched on 16 November 1996, to hopefully reach Mars on 12 September 1997, but re-entered the atmosphere east of Iquique in north Chile on 17 November 1997, carrying 270g of plutonium; as part of NASA's Systems for Nuclear Auxiliary Power, the satellite Transit 5BN-3 with a SNAP-9A nuclear power source, launched from Vandenberg Air Force Base (since May 2021, Vandenberg Space Force Base) in California, and never reached orbit on 21 April 1964, dispersing 1 kg of plutonium-238; the Iridium satellite constellation of 66 telecommunication satellites and the proposed Teledesic scheme; a damaged satellite could cause the catastrophic Kessler syndrome; John Muratore and the NASA X-38.
== Structure == Cyclotides have a well-defined three-dimensional structure due to their interlocking disulfide bonds and cyclic peptide backbone. Backbone loops and selected residues are labeled on the structure to help orientation. The amino acid sequence (single-letter amino acid representation) for this peptide is indicated on the sequence diagram to the right. One of the interesting features of cyclic peptides is that knowledge of the peptide sequence does not reveal the ancestral head and tail; knowledge of the gene sequence is required for this. In the case of kalata B1 the indicated glycine (G) and asparagine (N) amino acids are the terminal residues that are linked in a peptide bond to cyclize the peptide.
== Flatworms == Parenchyma is the tissue made up of cells and intercellular spaces that fills the interior of the body of a flatworm, which is an acoelomate. This is a spongy tissue also known as a mesenchymal tissue, in which several types of cells are lodged in their extracellular matrices. The parenchymal cells include myocytes, and many types of specialised cells. The cells are often attached to each other and also to their nearby epithelial cells mainly by gap junctions and hemidesmosomes. There is much variation in the types of cell in the parenchyma according to the species and anatomical regions. Its possible functions may include skeletal support, nutrient storage, movement, and many others.
=== Histology === Histologically speaking, it is characterized as dense connective tissue made primarily of type 1 collagen fibers. The collagen of the sclera is continuous with the cornea. From outer to innermost, the four layers of the sclera are:
==== Monoclonal antibodies ==== Monoclonal antibodies have long been considered for OI, but as of 2021, such therapy has not been approved for OI, neither in the European Union nor in the United States. Thus, it is unclear whether they are safe or effective. Among the monoclonal antibodies that have been studied are romosozumab (targets sclerostin, by Amgen), fresolimumab (TGF-β, Sanofi), blosozumab (sclerostin, Lilly), and setrusumab (sclerostin, begun by Novartis). Setrusumab, formerly known as BPS-804, is a monoclonal antibody that targets sclerostin, and has been studied in OI specifically more than any of the others. In the body, sclerostin binds to the LRP5 and LRP6 receptors, resulting in inhibition of the Wnt signaling pathway. This decreases bone formation, and is not a problem when a person has healthy bones. It is thought, though, that decreasing the concentration of sclerostin in the body may lead to the formation of more bone, and that is the premise as to why monoclonal antibodies that reduce the concentrations of naturally occurring sclerostin may help strengthen OI bone. While setrusumab was first developed at the pharmaceutical company Novartis, Novartis sold its rights to patent the drug to Mereo Biopharma in 2015, who has continued its development in conjunction with Ultragenyx. In 2019, Mereo announced that it had concluded collecting data for its phase II-B trial of setrusumab; the study was completed on 12 November 2020.
Sources: en.wikipedia.org
== Further reading == William P. Kirk "Krypton 85: a Review of the Literature and an Analysis of Radiation Hazards", Environmental Protection Agency, Office of Research and Monitoring, Washington (1972)
Economists have frequently highlighted the risks of redundancies from AI, and speculated about unemployment if there is no adequate social policy for full employment. The Economist said in 2015 that "the worry that AI could do to white-collar jobs what steam power did to blue-collar ones during the Industrial Revolution" is "worth taking seriously". Jobs at extreme risk range from paralegals to fast food cooks, while job demand is likely to increase for care-related professions ranging from personal healthcare to the clergy. In July 2025, Ford CEO Jim Farley predicted that "artificial intelligence is going to replace literally half of all white-collar workers in the U.S." According to the Stanford Digital Economy Lab in 2026, early-career workers showed decreasing employment rates in some AI-exposed occupations. In April 2023, Rest of World reported that 70% of the jobs for Chinese video game illustrators had been eliminated by generative artificial intelligence.
On 18 January, ambassadors from all 27 member states of the EU held an emergency meeting on Trump's threats. After Trump reversed his decision on implementing tariffs, EU officials were sceptical, but announced on 22 January that approval of the trade agreement would resume.
==== Muscle fibers ==== Typically muscle fibers surround the hydrostatic body. There are two main types of muscle fibers orientations that are responsible for the movement: the circular orientations and longitudinal orientations. Circular muscles decrease the diameter of a hydrostatic body, resulting in an increase in the length of the body, whereas longitudinal muscles shortens the length of a hydrostatic body, resulting in an increase in the diameter of the body. There are four categories of movements of a hydrostatic skeleton: elongation, shortening, bending and torsion. Elongation, which involves an increase in the length of a hydrostatic body requires either circular muscles, a transverse muscle arrangement, or radial muscle arrangement. For a transverse muscle arrangement, parallel sheets of muscle fibers that extend along the length of a hydrostatic body. For a radial muscle arrangement, radial muscles radiate from a central axis along the axis perpendicular to the long axis. Shortening involves the contraction of the longitudinal muscle. Both shortening and bending involve the contraction of longitudinal muscle, but for bending motion some of the antagonistic muscles work synergistically with longitudinal muscles. The amplitude of movements are based upon the antagonistic muscles forces and the amount of leverage the antagonistic muscle provides for movement. For the torsion motion, muscles are arranged in helical layers around a hydrostatic body.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.